Research Article
Adjuvant Iodine131 Lipiodol after Resection of Hepatocellular Carcinoma
Table 1
Patient characteristics.
| | Surgery only | Surgery + I131-lipiodol | Significance ( value) |
| Number | 52 | 58 | | Age, mean and SD | 58 (14) | 55 (12) | 0.23 | Sex, (M/F) | 36/16 | 44/14 | 0.29 | AJCC (2010) stage, | | | | 1 | 23 | 32 | 0.34 | 2 | 14 | 17 | 0.83 | 3a | 9 | 5 | 0.25 | 3b | 1 | 2 | 1.0 | 3c | 5 | 2 | 0.25 | Tumor size (mm), median and range | 46.5 (15–150) | 35.0 (15–110) | 0.55 | Resection margin (mm), median and range | 5.5 (0.050–43) | 5 (0.10–45) | 0.81 | Multifocality, | 20 | 15 | 0.22 | Microvascular invasion, | 18 | 19 | 0.50 | Major vascular invasion, | 2 | 2 | | Differentiation, | | | | Well | 10 | 11 | 1.0 | Moderate | 32 | 33 | 0.70 | Poor | 9 | 14 | 0.35 | Not stated/unknown | 1 | 0 | 0.47 | Race, | | | | Asian | 28 | 40 | 0.042 | Caucasian | 20 | 14 | 0.15 | Other | 4 | 4 | 1.0 | Chronic liver disease, | | | | Hepatitis B | 27 | 34 | 0.57 | Hepatitis C | 11 | 16 | 0.51 | Other | 14 | 8 | 0.10 | Child-Pugh stage, | | | | A | 51 | 58 | 0.47 | B | 1 | 0 | | Cirrhosis, | 26 | 31 | 0.43 | Serum AFP, median and range | 10.75 (0–13241) | 28 (1–7281) | 0.39 |
|
|